|
Srini Akkaraju is a Managing Director and concentrates on
biopharmaceuticals investments. Srini joined New Leaf in
January 2009. Prior to joining New Leaf, Srini was a
co-founder and Managing Director at Panorama Capital. Before
forming Panorama, Srini served as Partner of J.P. Morgan
Partners, where he was responsible for leading venture
investing in biotech companies. Earlier, Srini held business
and corporate development positions at Genentech. During his
tenure at Genentech, Srini was responsible for worldwide
partnering activities, in-licensing of therapeutics and
out-licensing of development projects. In addition, he also
was a founding member of BioStreet, an online marketplace
for biotech opportunities.
Srini is the author of a number of peer-reviewed articles,
including ones published in Science and Nature. He received
B.A. degrees in both Biochemistry and Computer Science from
Rice University and M.D. and Ph.D. degrees in Immunology
from Stanford University School of Medicine.
Board Seats:
Presidio Pharmaceuticals,
Synageva BioPharma
Contact Information:
srini@nlvpartners.com
(650) 234-2700
|
 |
